NCT05298033 - Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 7, 2022

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions

Vitiligo

Interventions

DRUG

Crisaborole 2 % Topical Ointment

Twice daily crisaborole 2% topical ointment

DRUG

PF-07038124 0.01% topical ointment

Twice daily PF-07038124 0.01% topical ointment

DEVICE

NBUVB phototherapy

Home narrow band UVB phototherapy exposure sessions 3 times per week

DEVICE

Sham phototherapy

Non-NBUVB visible light radiation exposure sessions 3 times per week

DRUG

Vehicle

Twice daily vehicle ointment

Trial Locations (1)

University of Colorado Anschutz - Clinical and Translational Research Centers, Aurora